Efficacy and safety of doravirine/islatravir in heavily treatment-experienced participants living with HIV-1: results from a randomized trial

Authors

Institutions

Publication Details

Journal
AIDS
Published
2025-10-01
DOI
https://doi.org/10.1097/qad.0000000000004367
Primary Topic
HIV Research and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Efficacy and safety of doravirine/islatravir in heavily treatment-experienced participants living with HIV-1: results from a randomized trial

Ernest Asante‐Appiah, И. М. Хаертынова, Todd Correll, Andrew Carr et al.
AIDS
HIV Research and Treatment
article

Efficacy and safety of doravirine/islatravir in heavily treatment-experienced participants living with HIV-1: results from a randomized trial

Ernest Asante‐Appiah, И. М. Хаертынова, Todd Correll, Andrew Carr, Princy Kumar, Rosie Mngqibisa, Ying Zhang, Wayne L. Greaves, Shariq Haider
article en

Abstract

No abstract available for this paper.
AIDSVol. 40(2)
Merck & Co., Inc., Rahway, NJ, USA (United States) (US), Georgetown University (US), St Vincent's Hospital Sydney (AU), Kazan State Medical Academy (RU), King Edward VIII Hospital (ZA), McMaster University (CA)
Openalex Percentile: Top 71%
HIV Research and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.